Companies Dominating the Germ Cell Tumor Market
- Eli Lilly and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- BioNTech SE
- ImmunoGen Inc.
- Teva Pharmaceutical Industries Ltd.
- Accord Healthcare Limited
- Sandoz International GmbH
- Lundbeck A/S
- Pfizer Inc.
- Merck & Co.
- Kyowa Hakko Kirin Co., Ltd.
- Baxter International Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Immunogen Inc. announced that the US Food and Drug Administration has granted an accelerated approval for ELAHERETM for the treatment of adult patients with folate receptor alpha positive, platinum resistant epithelial ovarian fallopian tube or primary peritoneal cancer who have received one to three prior systemic therapy regimens.
- BioNTech SE reported data from its ongoing first-in-human Phase 1/2 study evaluating the safety and preliminary efficacy of the company's new CAR-T cell therapy candidate, BNT211, in patients with advanced solid tumours. Preliminary results showed an encouraging safety profile and antitumor activity in patients with testicular cancer at the first dose levels of BNT211 evaluated.
